Profound symptomatic bradycardia associated with combined mibefradil and beta-blocker therapy.
We report two cases where the addition of mibefradil to long term beta-blocker therapy in managing hypertension produced profound symptomatic bradycardia requiring cardiac pacing. Reports of a number of interactions between mibefradil and other cardioactive drugs have now led to its withdrawal from the market worldwide.
Rogers
R
R
Sir Charles Gairdner Hospital, Nedlands, WA.
Prpic
R
R
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects*; D000368:Aged; D001562:Benzimidazoles / Q000009:adverse effects*; D001919:Bradycardia / Q000139:chemically induced* / Q000503:physiopathology / Q000628:therapy; D002121:Calcium Channel Blockers / Q000009:adverse effects*; D002304:Cardiac Pacing, Artificial; D004359:Drug Therapy, Combination; D004562:Electrocardiography; D005260:Female; D006801:Humans; D020748:Mibefradil; D008875:Middle Aged; D013764:Tetrahydronaphthalenes / Q000009:adverse effects*; D014665:Vasodilator Agents / Q000009:adverse effects*
D000319:Adrenergic beta-Antagonists; D001562:Benzimidazoles; D002121:Calcium Channel Blockers; D013764:Tetrahydronaphthalenes; D014665:Vasodilator Agents; D020748:Mibefradil